April 6, 2012 — Positron Corp. announced the approval of its Nuclear Regulatory Commission (NRC) manufacturing and distribution license amendment for the company's radiopharmaceutical manufacturing facility in Crown Point, Ind.
Positron received its pharmacy license from the Indiana Board of Pharmacy in December 2011, which served as a precursor to the NRC amendment and recent approval, allowing Positron to manufacture and distribute radiochemicals and radiopharmaceuticals throughout the United States. The company is currently producing Indium 111 Oxyquinoline for customer evaluation and commercial sale, with plans to process additional radioisotopes for medical use.
"This NRC approval completes the mandatory requirements qualifying our Crown Point site as a fully licensed and operational radiochemical manufacturing facility," said Scott Stiffler, Positron vice president of pharmaceuticals. "The capabilities at the Crown Point facility will play a vital role in Positron's expansion into radiopharmaceutical and radiochemical production and further development of products relevant to our full solution strategy. We expect sales of Indium Oxyquinoline to commence in the coming quarter."
For more information: www.positron.com
June 02, 2026 
